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Abstract 
NMDA receptor antagonists such as Ketamine and PCP are potent psychoactive 
drugs used recreationally. This class of drug induces a number of phenomena in humans 
similar to those associated with schizophrenia including reduced selective attention, 
altered working memory, thought disorders and hallucinations. These psychotomimetic 
drugs have thus been used as a longstanding model to study this disease in animals. 
Importantly, such animal models allow for recording of brain activity using invasive 
techniques that are inappropriate in humans. Previous electrophysiological studies have 
shown that MK-801, a potent non-competitive NMDA receptor antagonist, increases 
gamma-frequency oscillations and produces a state of disinhibition in the prefrontal 
cortex of rats wherein the activity of putative excitatory pyramidal neurons increases 
while the activity of putative inhibitory interneurons decreases. These features are 
relevant to schizophrenia because molecular evidence suggests dysfunction of inhibitory 
cortical interneurons, while electroencephalographic recordings show altered gamma-
frequency oscillations in this disease. It has been hypothesized that the disinhibited 
cortical state produces “noisy” information processing, but this has not been directly 
observed in the interaction of neuronal firing in either humans or animal models. We 
therefore tested this hypothesis by examining the synchronization of neural activity in the 
NMDA receptor antagonist model of schizophrenia. We used high-density 
electrophysiological recordings in the medial prefrontal cortex of freely moving rats 
before and after systemic injection of MK-801. Analysis of these recordings revealed that 
drug administration: (i) increases gamma power in field potentials in a manner 
dissociated from increased locomotion; (ii) does not change the gamma power in multi-
unit activity; (iii) decreases spike synchronization among putative pyramidal neurons in 
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the gamma range (30ms), and despite of this it (iv) does not change the synchronization 
between gamma-range field potentials or between sum-of-spikes and field potentials. 
These effects in synchronization may be revealing of potent cognitive effects associated 
with NMDA receptor antagonism, and may reflect impaired communication processing 
hypothesized to occur in schizophrenia. 
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2 Introduction 
2.1 Psychotomimetic effects of NMDAR Antagonists 
Phencyclidine (PCP) and ketamine are drugs first introduced as dissociative 
anesthetics that subsequently acquired an illicit, recreational use. They are both 
antagonists for the N-methyl-D-aspartate (NMDA) subtype of receptor for glutamate, the 
predominant excitatory transmitter in the brain. Because of severe adverse effects 
(including postoperative psychoses and dysphoria), the clinical use of PCP was 
discontinued in humans and replaced by ketamine, which is also a dissociative anesthetic 
but lacks many of the undesired effects of PCP. Yet the recreational use of PCP has 
prevailed over the years. Between 2004 and 2009, emergency departments in the United 
States received nearly 28,000 visits/year involving PCP intake (SAMHSA, 2009). In 
2011, the prevalence of illicit use of PCP was 1.3% and that of ketamine was 1.7% 
among a population of 12
th
 graders (Johnston, O'Malley, Bachman, & Schulenberg, 2012) 
PCP and ketamine are considered to be psychotomimetic drugs, as they transiently 
induce a number of phenomena in humans similar to those associated with schizophrenia. 
In subanesthetic doses, these drugs produce reduced selective attention, altered working 
memory, thought disorders, and hallucinations in healthy individuals, and exacerbate 
such symptoms in schizophrenic patients (Jentsch & Roth, 1999; Krystal et al., 1994; 
Malhotra et al., 1996). Originally developed as a neuroprotective and anticonvulsant 
substance, MK-801 is a non-competitive NMDA antagonist that shares chemical 
properties with PCP (Olney, Labruyere, & Price, 1989), and is now broadly used in 
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animal research as a psychotomimetic to gain insights into neurobiological and functional 
features of schizophrenia-like states. 
Much research on schizophrenia has focused on cognitive deficits because these are 
now thought to be the core features of the illness and the major predictor of long-term 
dysfunction associated with the disease (Keefe & Fenton, 2007). Schizophrenia is a 
severe brain disorder affecting nearly 1% of the world’s population (Lewis & Lieberman, 
2000). Symptoms associated with the disease are clinically grouped into three categories: 
i) positive, ii) negative, and iii) cognitive symptoms. Positive symptoms, also called 
psychotic symptoms, refer to those symptoms that appear to reflect an excess or 
distortion of normal functions; these represent the most dramatic clinical feature of 
schizophrenia and include hallucinations (perceptions not connected to an external 
stimulus), delusions (beliefs firmly held despite of evidence to the contrary), thought 
disorders (abnormal fluency and production of language), and abnormal psychomotor 
activity (usually manifested as grossly disorganized behavior, posturing, and/or 
catatonia). Negative symptoms reflect a diminution or absence of normal function, 
including social withdrawal, alogia (poverty in the content of speech), avolition (lack of 
initiative, or motivation to pursue meaningful goals), blunted affect (reduced capacity to 
recognize and express emotional states), and anhedonia (reduced capacity to experience 
pleasure). Finally, cognitive symptoms involve functional impairments such as poor 
executive functioning (the ability to process information to make decisions), reduced 
selective attention, and altered working memory. Many of the phenomena spanning these 
three domains are thought to depend on neuronal processing involving the prefrontal 
cortex; this structure has thus been a focus of investigation into the pathogenesis of 
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schizophrenia. Indeed, schizophrenic subjects show abnormal activation of PFC on 
cognitive tasks requiring working memory (Uhlhaas & Singer, 2010). Furthermore, the 
ability of NMDA antagonists to induce a number of similar cognitive phenomena has led 
to the hypothesis that these may share common neural substrates (Olney, Newcomer, & 
Farber, 1999). 
2.2 Functional and neurochemical changes 
NMDA receptors are found at post-synaptic terminals, and they mediate excitatory 
synaptic transmission in both inhibitory (interneurons) and excitatory (pyramidal) 
neurons in mammalian neocortex (Riedel, Platt, & Micheau, 2003). NMDAR pores open 
allowing cations to flow into the cell, thereby supporting depolarization of membrane 
potential, provided two conditions are met simultaneously: i) binding of glutamate and 
glycine to the receptor, and ii) removal of the magnesium block by depolarization of the 
membrane. Consequently, disruption of NMDAR function can be accomplished by 
blocking the binding sites of the receptor or by non-competitively blocking the ion 
channel of the receptor, thereby impeding trans-membrane ion flux (Foster, 1987). 
Unsurprisingly, the excitability of individual interneurons and pyramidal neurons is 
reduced by NMDAR antagonists when measured in acute brain slice preparations 
(Arvanov & Wang, 1997; Chen, Muhlhauser, & Yang, 2003). However, recordings in 
awake rats show increased cortical activation after administration of NMDAR 
antagonists (Jackson, Homayoun, & Moghaddam, 2004). Subsequent studies have shown 
that only the putative pyramidal neurons have increased activity under such drugs 
(Homayoun & Moghaddam, 2007) whereas the putative inhibitory fast spiking (FS) 
interneurons decrease their activity. Furthermore, the suppression of interneuron activity 
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was found to precede that of pyramidal neurons by several minutes, suggesting that 
interneurons are more susceptible to NMDAR antagonists as compared to pyramidal 
neurons (Homayoun & Moghaddam, 2007). These data indicate that the hyper-
excitability of pyramidal neurons is a consequence of altered network dynamics rather 
than a direct effect of the drug on the membrane excitability of pyramidal neurons. This 
is likely due to a state of disinhibition, wherein the drug suppresses the activity of 
inhibitory interneurons, thereby reducing inhibition on pyramidal neurons such that these 
increase their firing (Figure 1). 
 
Figure 1: Feedback inhibition model in a PFC local network. Left: Pyramidal 
neurons (PYR) release excitatory neurotransmitter onto GABAergic interneurons (FS); 
FS release inhibitory neurotransmitter onto PYR. Excitation of PYR activates FS and 
exerts inhibition back to PYR. Right: In the presence of NMDA receptor antagonist, FS 
excitation is reduced, and the feedback inhibition becomes disrupted. As a consequence, 
the net excitability of PYR is increased. 
Two factors may contribute to this disinhibitory effect: Higher sensitivity to NMDAR 
antagonists by interneurons (Rujescu et al., 2006), and the divergent and potent inhibition 
provided by interneurons to pyramidal neurons (Homayoun & Moghaddam, 2007). FS 
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interneurons have higher levels of the NMDA NR2A subunit than pyramidal neurons 
(Kinney et al., 2006), and this subunit is more responsive to NMDAR antagonist than the 
type more commonly found on pyramidal neurons (Xi, Zhang, Wang, Stradtman, & Gao, 
2009). It has therefore been proposed that interneurons have higher sensitivity to 
NDMAR antagonists than pyramidal neurons (Nakazawa et al., 2011). This differential 
sensitivity may underlie the disinhibited state produced by NMDAR antagonist. The 
reduction of interneuron activity by NMDAR antagonists will reduce inhibition on many 
pyramidal neurons. This reduction may overshadow the inhibitory effect exerted directly 
by NMDAR antagonist on individual pyramidal neurons. 
NMDAR affect gamma oscillatory activity (Hakami et al., 2009). Gamma rhythms 
are of particular interest because they modulate during performance of many cognitive 
tasks in normal subjects (Fitzgibbon, Pope, Mackenzie, Clark, & Willoughby, 2004), and 
they are altered in subjects with schizophrenia (Uhlhaas et al., 2009) and those 
administered NMDAR antagonists (Hong et al., 2009). For example, schizophrenic 
subjects show reduced gamma power in EEG recorded from frontal cortex during some 
tests of auditory perception (Kwon et al., 1999). Other groups have reported reduced 
phase synchrony of frontal cortex gamma in these subjects during perception tasks 
(Uhlhaas et al., 2006). However, other groups have reported increased gamma power 
during working memory  tasks (Barr et al., 2010). Collectively, these data suggest that 
prefrontal cortical processing is altered in patients with schizophrenia, particularly in the 
gamma frequency range, but it remains to be determined why the change in gamma 
power is inconsistent across studies. 
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Gamma oscillations are generated through processes involving feedback inhibition on 
pyramidal neurons by a class of interneurons expressing parvalbumin (PV) (Tamás, Buhl, 
Lorincz, & Somogyi, 2000). When NMDAR are deleted from these interneurons in 
transgenic mice, baseline cortical gamma oscillations are increased in amplitude (Carlen 
et al., 2011). Furthermore, antagonizing NMDAR with sub-anesthetic doses of either 
ketamine or MK-801 increases gamma frequency oscillations in PFC of freely moving 
rats (Pinault, 2008). These substances also dose dependently increase gamma power in 
field potential recordings from motor, somatosensory and visual cortices in freely moving 
or anesthetized rats (Hakami, et al., 2009). Thus, the cellular and molecular evidence for 
deficient processing in PFC PV interneurons may account for the altered gamma EEG in 
schizophrenia by producing a state of disinhibition (Gonzalez-Burgos, Fish, & Lewis, 
2011) similar to what is proposed to occur with NMDA antagonists (Homayoun & 
Moghaddam, 2007). 
Gamma oscillations affect neuronal signaling in prefrontal cortex. For instance, the 
generation of action potentials by pyramidal neurons in this structure synchronizes with 
the phase of gamma field potential rhythms (Denker, Roux, Timme, Riehle, & Grün, 
2007). It has been suggested that such synchronization is important for the representation 
of information by groups of cortical neurons (Fries, 2005). The alteration of gamma 
rhythms owing to a state of cortical disinhibition has thus been proposed to degrade 
neuronal processing and produce a ‘noisy’ encoding of information (Gandal, Edgar, 
Klook, & Siegel, 2011; Gruber et al., 2010; Hakami, et al., 2009). This hypothesis 
remains to be directly tested with recordings of action potential firing. Here, we test this 
7 
 
hypothesis in a rodent model of cortical disinhibition induced by systemic administration 
of MK-801.  
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3 Methods 
3.1 Subjects and surgical procedure 
Three male Brown Norway rats and one Brown Norway/Fisher 344 hybrid rat (5-7 
months old, weighting 300-370g at the time of the surgery) were individually housed in 
home cages in a 12h reversed light-dark cycle room. Each rat was anesthetized with 1-2% 
isoflurane in oxygen at a flow rate of 1.2-2.5 L/minute and placed in a stereotaxic holder. 
Lidocaine (0.1ml SC) was injected under the scalp prior to making an incision along the 
midline to access the skull. Craniotomies were made to allow recording electrodes to 
target the mPFC (3.2mm AP and 1.2mm ML right from Bregma at 9° angle toward the 
midline; Figure 2). Screws were implanted in the skull for structural support and to 
provide attachment of ground wires. A polymer-based adhesive (MedaBond) was applied 
to increase adhesion of dental acrylic to bone and the screws. Drives containing 12-18 
individual-drivable tetrodes and 2 drivable references were chronically implanted on the 
skull using dental acrylic. Recording electrodes were lowered 0.5-1mm ventral from 
brain surface immediately after the surgery and subsequently lowered up to 3-4mm over 
the course of 2-3 weeks to reach the target region. Rats received post-surgical treatment 
for 2 days consisting of Metacam (1mg/kg, SC, 2 times a day), Convenia (0.1ml/kg, SC, 
once a day), and Buprenorphine (0.03mg/kg, SC, 1 time pre-surgery and 1 time during 
recovery). Post-mortem histology using cresyl violet was used to visualize electrode 
tracks so as to assess the positioning of the electrodes. 
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Figure 2: Illustration showing the target region for the recording electrodes. 
Arrow indicates the target of recording electrodes in the lateral prelimbic region of 
frontal cortex. Adapted from Paxinos & Watson, 2007. 
3.2 Behavior, electrophysiology and data pre-processing 
Experiments were conducted in freely moving rats in a dimly lit room. Neuronal 
activity was recorded while animals explored a circular arena 1m in diameter restricted 
by a wall. Foraging was encouraged by sparse distribution of chocolate sprinkles across 
the arena. A motorized commutator was used to allow subjects to rotate freely during 
electrophysiological recordings. A video tracking system was used to record the position 
and movement of rats during the recording. 
Rats were allowed to explore the open field for 30 minutes, then administered either 
MK-801 (0.75-0.1mg/kg in 0.2ml/kg of vehicle) or vehicle (saline, 0.2ml/kg of 0.9% 
NaCl) intraperitoneally, and returned shortly after to the arena for another 50 minutes. 
We then analyzed neuronal recording data from the last 20 minutes of the post-injection 
period so as to allow the drug to take effect, and compared this to the 20 minute period 
prior to injection (Figure 3). 
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Figure 3: Illustration showing the experimental design. Experiments lasted 80 
minutes with a brief interruption for injection of drug or saline. Only 20 minutes in the 
pre- and post-injection periods were used in the analysis (gray regions). 
Signals from intracortical electrodes were first amplified by a unity-gain headstage 
(Neuralynx) to reduce noise susceptibility during signal transmission to the data 
acquisition system (Neuralynx Cheetah) via a multi-wire cable and a commutator 
(Neurotek) mounted on the ceiling. Input signals were amplified 1250 times, digitized at 
32000 Hz, and band-pass filtered differently for field potentials and spike before saving 
to a computer hard drive. For the field potentials, the signal was band-pass filtered 
between 1-1000 Hz and downsampled to 2000 Hz. For spike data, the signal was filtered 
between 600-6000 Hz and 2ms-long samples were recorded whenever the amplitude of 
the signal crossed a pre-defined threshold between 35-50µV (depending on noise level of 
each electrode). 
The position of the rat in the arena was recorded for the duration of the neuronal 
recording using a video tracker system (Neuralynx). 
3.3 Data analysis 
Data were further processed (Figure 4) for off-line analysis using Maltab 
(Mathworks) software and open-source Matlab toolboxes for computing spectra 
(Chronux toolbox; Bokil, Andrews, Kulkarni, Mehta, & Mitra, 2010) and circular 
statistics (CircStat; Berens, 2009). Field potential data were first band pass filtered (4-200 
In
je
ct
io
n
Analysis
20 min
Analysis
20 min
Pre-injection
30 min
Post-injection
50 min
11 
 
Hz) using a zero-phase digital filter. Power spectra of field potentials were computed by 
the fast Fourier transform algorithm using a standard multi-taper windowing method on 
100 non-overlapping segments of 3s randomly sampled from the filtered field potential 
for each epoch (pre-injection or post-injection). Confidence intervals of the power spectra 
were computed by Jackknife error estimates. To investigate the effect elicited in the 
gamma-band, analyses were limited to the frequency range 30-100 Hz. The relative 
change in gamma-band power (ratio of the power in the post-injection period to power in 
the pre-injection period) was used to account for variability in field potential amplitude 
between recording sessions when displaying population averages. Two-way analysis of 
variance (ANOVA) with repeated measures was used for statistical comparisons. 
Cross-correlations between field potentials and sum-of-spikes were calculated for 
investigating whether spike firing synchronizes with gamma field potentials. We also 
used a standard procedure for detecting spike-triggered phases of gamma field potential 
(Denker, et al., 2007). First, a Hilbert transform was used to extract the instantaneous 
phase of field potential data that was band-pass filtered (30-100 Hz) with the zero-phase 
filter to isolate gamma-range phenomena. For each recorded neuron, spikes were 
subsampled in the period with higher number of spikes to normalize firing rates so that 
resultant computations were not strongly influenced by a few neurons with high firing 
rates. Then we constructed a normalized circular distribution of the spike-triggered 
phases. It was considered to be phase locked if this distribution was found to be non-
uniform by Rayleigh's test for non-uniformity. For neurons with significant phase 
locking, the preferred phase angle was the direction of the mean vector and the phase 
locking value (PLV) was its magnitude. 
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Figure 4:  Flow diagram for data processing. Pre-processing occurs at the time of 
data acquisition. See text for details. 
Action potential waveforms were classified as belonging to individual neurons using 
computer algorithms and subsequent manual verification. First, a clustering algorithm 
(KlustaKwik; Harris, 2002) was used to group spike waveforms into clusters based on 
numerous waveform features.  A modified version of an open-source software (MClust, 
Redish & Schmitzer-Torbert, 2002) was then used to manually merge, split, or delete 
clusters based on standard assumptions about the electrophysiology of action potentials. 
Single-unit activity was transformed into a binned representation (30ms bin size) to 
resolve short-range interactions associated with gamma frequencies (>30Hz). A z-score 
transform was then applied to normalize firing rates so that resultant computations were 
not strongly influenced by a few neurons with high firing rates. Zero-lag correlations 
provided a measure of synchronization between neurons (Figure 5). 
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Figure 5: Visual representation of cross-correlation method. Fictive trains of 
spikes from different neurons are represented by horizontal lines of squares. Each square 
represents a bin of time in which a spike occurred (black) or did not occur (gray). When 
the trains are aligned (top) three coincidences (upward arrow) occur in this example. By 
shifting the trains to the left (lag = 1, middle or lag = 2, bottom) other coincidences may 
occur. Repeating this process for additional lags provides information about the temporal 
relationship between two different neurons. Cross-correlation measures are computed in a 
similar way except that they assign higher values to coincidences where bins contain 
more than one spike. Positive cross-correlations indicate co-activation between two 
neurons. Negative cross-correlations indicate that the activation of one neuron coincides 
with ‘pauses’ of a second neuron. 
To determine the statistical significance of individual correlations, 95% confidence 
intervals were estimated by repeatedly randomly shuffling the inter-spike intervals of the 
two spike trains and re-computing correlations. To asses if drug administration affected 
the population of correlations, we tested the null hypothesis that the distribution of 
correlation values was not different before as compared to after drug administration using 
the Kolmogorov-Smirnov test. 
Finally, running speed was calculated as the average of one second trace of 
“instantaneous” speeds (ratio of change in position by change in time of contiguous 
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records). We used a two-way repeated measures analysis of covariance (ANCOVA) to 
control for the hypothesized speed covariate of gamma power. 
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4 Results 
We recorded neuronal activity in mPFC of 4 rats over 15 sessions of foraging. Each 
session contained an epoch before injection, and an epoch after injection. Injections 
contained either MK-801 (0.075 mg/kg or 0.2 mg/kg) or saline as a control. We used 
multiple measures to assess changes in neuronal synchronization as a result of the drug 
administration. 
4.1 Field potential power 
Consistent with previous studies (Hakami, et al., 2009; Nicolás et al., 2011; Pinault, 
2008), administration of MK-801 significantly increased the power of gamma-frequency 
(30-100 Hz) oscillations of field potentials as compared to effects evoked by saline 
injection (population data, n = 12 sessions; ANOVA, p < 0.003; Figure 6). 
 
Figure 6: Drug-evoked increase in mPFC gamma oscillations. Left panel: Power 
spectra before (gray area) and after MK-801 injection (black area) for a typical recording. 
Right panel: Relative change in gamma-band power following injection of saline (gray) 
or MK-801 (black) show a significant increase following drug as compared to saline 
(population data, n = 12 sessions; ANOVA, p < 0.003). Error bars represent 95% 
confidence intervals. 
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Previous studies have shown that systemic administration of NMDAR antagonist can 
induce motor hyperactivity, and gamma power has been reported to increase with running 
speed in rats (Hakami, et al., 2009; Nicolás, et al., 2011). Considering that the peak of 
locomotor activity and the peak of gamma power occurred with a delay of minutes, and 
that the change in gamma power was also demonstrated in anesthetized animal under low 
dose of ketamine, it was suggested that hyperlocomotion and the increase in gamma are 
two independent effects of the treatment (Hakami, et al., 2009). In agreement with those 
studies, the mean speed significantly increased following MK-801 administration (Figure 
7). We therefore sought to test if increased gamma power could be a result of increased 
running speed. We found that gamma power did increase with running speed in the 
absence of MK-801 effects (R
2
 = 0.18, p < 0.0001, Figure 8). Furthermore, a test for 
homogeneity of regression slopes did not reject the hypothesis that speed and gamma 
power covary (ANCOVA, p > 0.1), i.e., the slope of the regression lines for which speed 
is a predictor of power are not significantly different between subjects. Consequently, we 
partitioned out the variance due to speed and drug and still found significant differences 
in gamma power (ANCOVA, F(2,848) = 332.548, p < 0.0001), i.e., the increase in 
gamma power following MK-801 administration cannot be attributed to running speed. 
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Figure 7: Locomotor activity increases following MK-801 administration. Left: 
Trace showing typical running speed for the duration of one recording session (waiting 
periods not included in the analysis). Right: Mean speed significantly increased in the 
period following administration of MK-801 (population data, n = 8 sessions; ANOVA, p 
< 0.035). 
 
 
Figure 8: Relationship between running speed and gamma power (population 
data). Gamma power correlates with running speed in the absence of MK-801 effects. 
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4.2 Synchronization of gamma field potentials 
Because we found that the power of gamma field potential was altered by MK-801, 
we tested if the synchronization of field potentials within mPFC was also altered. We 
computed cross-correlations between field potentials. We did not find any significant 
difference at zero-lag (t-test, p > 0.9, Figure 9). 
 
Figure 9: Synchronization between gamma field potentials. Correlation of gamma 
field potential did not change after MK-801 injection (population data, n = 10 sessions; t-
test, p > 0.9). 
4.3 Firing rate 
Pyramidal neuron firing has been reported to increase after administration of 
NMDAR antagonist (Homayoun & Moghaddam, 2007); we verified that this effect also 
occurred in our data. We found increased firing rate after drug injection (t-test, p < 0.001, 
Figure 10). 
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Figure 10: MK-801 increased firing rate. Firing rate among neurons significantly 
increases after administration of MK-801 (population data, n = 254 neurons; t-
test, p < 0.001). 
4.4 Multi-unit gamma power 
As we found an increase in gamma power in the field potential, we wanted to know if 
there was likewise an increase in the power of the neuronal firing. Therefore we 
calculated the power of the sum-of-spikes from all neurons (multi-unit activity). We did 
not find a change in gamma power of multi-unit (t-test, p > 0.5, Figure 11). 
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Figure 11: Gamma power of multi-unit activity. There was no change of gamma 
power of multi-unit activity after MK-801 administration (population data, df = 15; t-test, 
p > 0.5) 
4.5 Synchronization of multi-unit activity to gamma field potential 
Our data show that MK-801 enhances gamma oscillations in the mPFC. Because 
pyramidal neuron firing has been reported to synchronize with gamma rhythms in mPFC 
in the absence of drugs (Denker, et al., 2007), we next investigated how such 
synchronization is affected by MK-801 administration by quantifying the correlation 
between multi-unit to gamma field potential.  
We did not observe a change in the correlation between multi-unit and gamma field 
potential (t-test, p > 0.9, Figure 12). 
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Figure 12: Cross-correlation field potential by multi-unit. No drug (gray line) and 
MK-801 (black line). The correlation at zero-lag is unaltered following drug injection 
(population data; n = 10; t-test, p > 0.9). 
4.6 Synchronization of neuronal firing 
To test if the state of cortical disinhibition induced by an NMDAR angatonist 
underlies ‘noisy’ information processing, we computed synchronization of neuronal 
firing among neurons in mPFC. We computed the cross-correlation of neuronal firing 
over lags of +/- 600 ms (Figure 13), which visually reveals some structure that is lost 
following drug administration. To quantify synchronization at timescales relevant to 
gamma rhythms (<30Hz), we binned spiking data at 30 ms and computed zero-lag 
correlations among all pairs of neurons. This procedure is designed to detect coincident 
neuronal firing at timescales corresponding to the low range of gamma rhythms, but will 
detect effects at higher frequencies as well. 
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Figure 13: Normalized cross-correlations between all pairs of simultaneously-
recorded neurons at different lags. Left: Before MK-801 injection. Right: After MK-
801 injection. 
The distribution of correlations for all simultaneously recorded neurons is different 
than the distribution of correlations computed from the same neurons after shuffling the 
order of the spike intervals, revealing both positive and negative correlations in the 
‘shoulder’ regions of the distribution (Kolmogorov-Smirnov test, p < 0.0001, Figure 14). 
Following administration of MK-801, the distribution of correlations are different from 
the pre-injection period (Kolmogorov-Smirnov test, p < 0.0001), wherein the distribution 
of positive correlations (e.g. right-side shoulder) more closely resembles that of the 
shuffled data as compared to the pre-injection distribution. This indicates a loss of 
positive correlations. No significant change was evoked by saline administration 
(Kolmogorov-Smirnov test, p > 0.64). 
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Figure 14: Probability distributions of zero-lag correlations among pairs of 
simultaneously-recorded neurons. Left: Probability distributions of zero-lag 
correlations among all pairs of simultaneously-recorded neurons before injection (gray), 
after MK-801 injection (black), and shuffled data (dotted line). The shoulder regions of 
distribution for non-shuffled data reveal structure in neural activity. Right: Cumulative 
probability distributions (CDF) of the probability distributions in the left panel, revealing 
that MK-801 injection produced a statistically different distribution of correlations 
(population data, n = 4608 pairs; Kolmogorov-Smirnov test, p < 0.0001). The pre-
injection CDF is always under the post-injection CDF which means that for every cross-
correlation pair before injection there is another pair with reduced value after drug 
injection. 
Two metrics where used to quantify the change in synchronization. First, we looked 
at the mean correlation at zero-lag and found a significant decrease following drug 
administration (p < 0.0001, Figure 15 - left). We also counted the number of neuronal 
pairs with significant correlations and also found a decrease after drug administration (p 
< 0.0001, Figure 15 - right). 
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Figure 15: Change in synchronization of neuronal firing. Left: Mean correlation at 
zero-lag is significantly reduced after drug administration (population data, t-test, n = 
4608 pairs, p < 0.0001). Right: The number of significantly correlated pairs is reduced 
after drug administration (population data, n = 4608 pairs; McNemar test, p < 0.0001). 
These data reveal decreased neuronal synchronization under a disinhibited state 
induced by NMDAR antagonist. 
  
25 
 
5 Discussion 
A leading hypothesis for the cortical pathophysiology presenting in schizophrenia is 
that a state of cortical disinhibition alters neural dynamics and impairs neuronal 
information processing by making neuronal encoding more ‘noisy’ (Gandal, et al., 2011; 
Gruber, et al., 2010; Hakami, et al., 2009; Winterer et al., 2004). Here, we assessed this 
hypothesis in foraging rats using high-density intracerebral recordings in the NMDAR 
antagonist model of schizophrenia, which produces a temporary state of disinhibition 
(Homayoun & Moghaddam, 2007). We found that gamma-frequency power of mPFC 
field potentials increase after administration of MK-801, but this is independent from the 
increase in running speed. We further found that this drug produces a decreased neuronal 
synchronization: Both the mean pair-wise correlations and the number of significantly 
correlated neurons decreased after drug administration. However, the correlation between 
sum-of-spikes (or multi-unit activity) and field potentials is unchanged by drug 
administration. Thus, even though the average activity before and after drug are 
comparable, the drug induces desynchronization in the fine temporal scale of the 
neuronal firing (Figure 16). 
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Figure 16: Illustration summarizing the effects of MK-801 administration on the 
synchronization of PFC activity. The changes occurring in a fine temporal scale are not 
evident in the averaged activity. Top: Spikes (vertical black traces) from different pairs of 
neurons are aligned and the average activity also tends to be aligned with the field 
potential oscillations. Bottom: Spikes from different pairs of neurons are not aligned to 
each other and yet the average activity remains aligned with the field potential 
oscillations. 
5.1 Spike-field coherence & information processing 
Spike-field synchronization may help facilitate information processing. 
Communication among groups of neurons has been proposed to occur more effectively 
when the spiking activity of neuronal populations is synchronized with its local field 
potential (Denker, et al., 2007; Fries, 2005; Gandal, et al., 2011). We hypothesized that 
such interactions would be revealed by synchronization among action potentials from 
different neurons over the time-scale of 30ms, which would account for polysynaptic 
No drug:
NMDAR antagonist:
Unchanged spike-field synchronization
Reduced spike-spike correlation
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interactions. Interestingly, our data indicates that under the influence of an NMDA 
antagonist, the increase in field potential gamma was not associated with an increase in 
synchronization of spike firing on short timescales. Also, it has been reported a decrease 
in spike-LFP coherence in both orbitofrontal cortex and anterior cingulate cortex in freely 
moving animals (Wood, Kim, & Moghaddam, 2012). This conflicts with our data that 
indicate no change in spike-field synchronization. This discrepancy may result from a 
difference in recording target, or more likely, a difference in data collection and analysis. 
Dysfunction of gamma rhythm is the most replicated finding in schizophrenia 
(Gandal, et al., 2011), and these are often reported to correlate with attention, working 
memory, and consciousness; functions that are impaired in the human disease (Uhlhaas, 
et al., 2009). Reports of the nature of the disruption of gamma oscillations are mixed – 
some groups find decreased power (Kwon, et al., 1999) or decreased phase 
synchronization (Uhlhaas, et al., 2006), while other report an increase in gamma EEG 
power (Barr, et al., 2010) in patients with schizophrenia. Many prominent research 
groups have focused on the decrease in gamma EEG power, and suggested that this is 
functional evidence of reduced neuronal synchronization (Gallinat, Winterer, Herrmann, 
& Senkowski, 2004; Haig et al., 2000; Lewis, Curley, Glausier, & Volk, 2011; Uhlhaas 
& Singer, 2010; Winterer, et al., 2004). This argument rests on the assumption that scalp-
recorded EEG power reflects synchrony among neuronal firing of action potentials. Our 
data indicate that this assumption is invalid for NMDAR-induced increases in gamma 
field potential power, and raises the possibility that it may not be valid in other 
circumstances as well. 
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We cannot discern from the present data set whether spike-spike correlations or 
gamma field potential power are more reflective of the psychotomimetic properties of 
NMDAR antagonists. It could very well be the case that the spike-spike correlations are 
more important and decrease in both the NMDAR antagonist model as well as in the 
clinical disease of schizophrenia, even though gamma power increases in the former and 
decreases in most studies of the latter. 
5.2 Motoric effects 
Field potential recordings over the frontal, parietal and occipital cortex show 
increases in both locomotion and gamma power under ketamine or MK-801 in rats 
(Hakami, et al., 2009, Nicolás, et al., 2011). Furthermore, gamma power increases with 
locomotion in the absence of such drugs (Figure 8; Hakami, et al., 2009). These data raise 
the possibility that the increase in gamma power may be attributable to the increased 
motoric output. However, the peak of locomotor activity and gamma power does not 
coincide in some studies, and the increased gamma power can be observed in 
anesthetized animals, suggesting that hyperlocomotion and the increase in gamma are 
two independent effects of the treatment (Hakami, et al., 2009). A more rigorous 
statistical procedure is needed to dissociate contributions of movement to the changes in 
gamma in the awake state. We considered the scenario in which gamma oscillatory 
activity is susceptible to locomotor activity. Using ANCOVA analysis to partition out the 
variance of gamma power attributable to running speed revealed that a strong effect on 
gamma remained, suggesting that much of the increased gamma in not attributable to 
running speed. 
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5.3 Potential mechanisms of NMDAR-mediated increase of gamma 
Sub-anesthetic doses of NMDAR antagonist increase the power of gamma 
oscillations (Hong, et al., 2009) while also mimicking some of the cognitive symptoms of 
schizophrenia (Krystal, et al., 1994). Indeed, systemic administration of NMDAR 
antagonist increases the power of gamma in both anaesthetized and awake rats, as well as 
slice preparations (Wood, et al., 2012; Hakami, et al., 2009; Pinault, 2008; Homayoun & 
Moghaddam, 2007; Arvanov & Wang, 1997). It has been suggested that the increase in 
gamma power is due to an imbalance of excitation/inhibition, which has been suggested 
to introduce spurious information flow in the spiking activity of local cortical networks 
(Gandal, et al., 2011; Gruber, et al., 2010; Hakami, et al., 2009; Winterer, et al., 2004). 
Why does antagonizing NMDAR, one of the primary excitatory post-synaptic receptors, 
increase pyramidal neuron activity and increase gamma frequency field potential 
oscillations? 
The increase in pyramidal neuron activity (Homayoun & Moghaddam, 2007) is likely 
due to a network effect in which the suppression of inhibitory interneuron activity 
releases inhibition onto pyramidal neurons, thus increasing their rate (Figure 1). The 
faster dynamics of AMPA receptors (AMPAR) as compared to NMDAR could explain 
the increase in gamma power. The decay time constant of NMDAR-mediated currents is 
generally reported to be approximately three times longer than the longest period of 
gamma (30ms; Wang, Stradtman, Wang, & Gao, 2008), indicating that its dynamics are 
too slow to support such oscillations. On the other hand, AMPAR-mediated currents are 
much faster by nearly an order of magnitude, phase lock tightly with gamma rhythms, 
and are sufficient to support this oscillatory activity (Rotaru, Yoshino, Lewis, 
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Ermentrout, & Gonzalez-Burgos, 2011). Results from computational simulations are 
consistent with this proposed mechanism. Short-lasting excitatory post-synaptic currents 
(EPSPCs) from AMPAR were found to be sufficient to produce gamma oscillations, 
whereas the slower currents generated by NMDAR reduces gamma power (Rotaru, et al., 
2011). By removing the slow kinetics of the NMDAR and allowing the faster mechanism 
of the AMPAR to take place, more neurons may become entrained and increase the 
power of gamma oscillations. Although we cannot rule out mechanisms originating in 
cortical afferents, the fact that NMDAR antagonists can increase gamma oscillations in 
acute slice preparations containing only frontal cortex (McNally, McCarley, McKenna, 
Yanagawa, & Brown, 2011) suggests that at least part of the effect is due to local cortical 
processing. 
  
31 
 
6 Conclusions 
We sought to test whether a state of cortical disinhibition evoked by systemic 
administration of an NMDAR antagonist would lead to desynchronized neuronal 
processing in prefrontal cortex. Indeed, we found that the spike-spike synchronization 
was reduced, despite finding an increase in gamma power of field potential and no 
change in gamma power of multi-unit. This is evidence against the common assumption 
that changes in scalp-recorded EEG power ubiquitously reflect changes in synchronized 
firing of action potentials, at least under the influence of NMDA antagonists. However, 
our results do support the hypothesis that cortical disinhibition induces less 
synchronization of spike firing, at least during some behaviors. This may correspond to 
‘noisy’ information coding hypothesized to present in schizophrenia (Gandal, et al., 2011; 
Gruber, et al., 2010; Hakami, et al., 2009; Winterer, et al., 2004). Investigating 
commonalities in aberrant neuronal synchronization induced by other drugs that can 
induce hallucinations and delusions, such as amphetamines and serotonin-increasing 
compounds, may shed further light on what aspects of neuronal signaling are tied to 
psychosis.  
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8 Appendices 
 
 
 
 
 
Figure 17: Power of gamma increases because amplitude of gamma increases. 
Left: Distribution of gamma amplitude changed after MK-801 administration so that 
more high amplitude oscillations occur as compared to before drug. Right: Cumulative 
distribution function accentuating the change in the distribution of amplitudes. Population 
data, n = 10; Kolmogorov-Smirnov test, p < 0.0001. 
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Figure 18: No change in field potential synchronization after MK-801 treatment. 
Left: Zero-lag correlation between gamma field potentials (46-54Hz) before and after 
MK-801 administration remains unchanged (population data, n = 10; t-test, p > 0.97). 
Right: Zero-lag correlation between gamma field potentials (30-90Hz) before and after 
MK-801 administration remains unchanged (population data, n = 10; t-test, p > 0.96). 
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Figure 19: Percentage of significant correlations before and after MK-801 
administration. Total number of significant correlations decreases after MK-801 
administration (PRE 20.44% vs. POST 14.17%). Number of new correlations (~PRE & 
POST 10.07%) is also smaller than the number of lost correlations (PRE & ~POST 
16.34%). 
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Figure 20: Probability distributions of zero-lag correlations among activity in 
recording tetrodes. Left: Probability distributions of zero-lag correlations among all 
tetrodes before injection (gray line), after MK-801 injection (black line), and shuffled 
data (dotted line). The shoulder regions of distribution for non-shuffled data reveal 
structure in neural activity. Right: Cumulative probability distributions (CDF) of the 
probability distributions in the left panel, revealing that MK-801 injection produced a 
statistically different distribution of correlations (population data, n = 739 pairs; 
Kolmogorov-Smirnov test, p < 0.0001). 
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Figure 21: No change in cross-correlation of multiunit activity between 
recording tetrodes after saline treatment. Left: Mean correlation at zero-lag is not 
changed after saline administration (population data, n = 756 pairs; t- test, p > 0.54). 
Right: Cumulative probability distributions (CDF) of the probability distributions in the 
left panel, revealing that saline injection did not produced a statistically different 
distribution of correlations (population data, n = 756 pairs; Kolmogorov-Smirnov test, p 
> 0.24). 
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Figure 22: Distribution of field potentials phases at the time of spiking for all 
tetrodes with significant PLV. Top: Mean phases are indicated with solid lines and 
histogram of phases as enclosed areas. Bottom: Percentage of significantly locked 
tetrodes before and after MK-801 injection. A significant decrease is observed for low 
frequency gamma (36-44Hz, p < 0.05; McNemar test) but not higher frequency 
oscillations (46-54Hz, p > 0.2 or 66-74Hz, p > 0.99; McNemar test). 
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Figure 23: Summary of findings. 
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